PharmAust Completes Scaled Manufacture of Monepantel Tablets for Phase I Clinical Trials in Dogs

- PharmAust settles on final tablet format for dogs.
- Catalent and PharmAust successfully scale batch method to producing 2000 tablets for the Phase I trials in healthy dogs.
- Scaled manufacture completed.

7th February 2019 – Perth, Australia: PharmAust Ltd (ASX:PAA), a clinical-stage oncology company, has finalised its monepantel tablet research, development and scaled manufacture.

Large-scale production has now been completed to provide the first batch of 2000 tablets sufficient for the Phase I trials in healthy beagle dogs. This work was conducted in collaboration with specialist US-based manufacturer Catalent, San Diego Inc.. The 2000 tablets will be used in the Phase I trials announced to commence on 19th February 2019.

PharmAust's Chief Scientific Officer Dr Richard Mollard commented, "Defining a process to manufacture a large number of tablets is an important step for PharmAust and the clinical trial program. The Phase I Clinical trial, determining the dose range anticipated to be compatible with anticancer blood level activity, can now commence with a standardised and regulatory compliant tablet.

The production of this tablet further paves the way for the next manufacturing round, to provide monepantel for the Phase II program and for determination of anticancer efficacy in pet owners' dogs with naturally occurring cancers".

Enquiries:

Dr Roger Aston
Executive Chairman and CEO
Tel: 0402 762 204
rogeraston@pharmaust.com

Dr Richard Mollard
Chief Scientific Officer
Tel: 0418 367 855
rmollard@pharmaust.com

About PharmAust (PAA):
PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company which generated ~Aus$3.02m in revenues in the 2018 FY.

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.

More products. Better treatments. Reliably supplied.™